Joseph Lasaga was appointed Executive Vice President and Chief Business Officer of Rigel Pharmaceuticals in January 2024. He is responsible for leading the Company’s business development, alliance management, program management and portfolio strategy functions. Mr. Lasaga has more than 25 years of pharmaceutical and biotechnology industry experience with a strong background in R&D, corporate development and strategy. Since rejoining Rigel in 2016 as Vice President of Business Development and Alliance Management, he has held roles of increasing responsibility, including Senior Vice President and Executive Vice President, Corporate Development. Prior to rejoining Rigel, Mr. Lasaga was Vice President, Business Development and Alliance Management at Galena Biopharma, Inc., where he led corporate and business development strategy and execution. From 2010 until 2014, he was Director and later named Senior Director, Business Development at Nektar Therapeutics, where he led licensing activities, managed key alliances and structured research collaborations. Mr. Lasaga began his career at Rigel in 1998 as a molecular biologist in discovery research, before transitioning into business development in 2005. During his earlier tenure at Rigel, he served as Associate Director of Business Development, acting as alliance manager for all of Rigel’s partners, leading various out-licensing initiatives and supporting a broad range of strategic transactions. Mr. Lasaga holds a B.S. in Molecular Biology from San Jose State University and a M.B.A. in Marketing from San Francisco State University.